) The Gene Expression Core represents a new Core facility for the UCCC and is most likely one of the first such cores to be peer-reviewed in the CCSG system. This facility is dedicated to making molecular gene expression technology available in a user-friendly manner. We utilize oligonucleotide arrays, cDNA arrays and quantitative RNA methodologies to investigate the changes in gene expression for our users. Affymetrix technology is used for the oligonucleotide arrays. These arrays are capable of analyzing human, mouse, rat and yeast species. Expressed sequence tag (EST) arrays of the mammalian species are available for gene discovery purposes. Custom cDNA arrays are constructed from sequence-verified clones. Quantitation of selected genes is made possible using real time PCR. With these capabilities, the objectives of the Gene Expression Core facility are to: 1) Analyze gene expression using both oligonucleotide and cDNA arrays; 2) Facilitate gene discovery with the inclusion of expressed sequence tag (EST) capability to the arrays; 3) Accurately quantitate gene expression using real time PCR; 4) Provide support for data analysis and bioinformatics by our data mining tool and our cluster analysis capabilities; 5) This facility has a commitment to utilizing a variety of approaches for expression analysis. This core was established in response to the technological advances in gene array, as well as the demand for high throughput expression analysis to investigate pathogenesis, therapeutics, genetic susceptibility and gene discovery in cancer research. The informatics aspect is of paramount importance, and three distinct analysis programs as well as a network are used to store and analyze the data. The facility has the capability and flexibility to adapt as the field of array technology changes. These changes are translated into upgrading the facility and its services. More complex analysis of gene expression arrays is available to members through the Biostatistics/Bioinformatics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-14
Application #
6491197
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications